Loading...

Incyte Corporation

INCY•NASDAQ
Healthcare
Biotechnology
$94.65
$-0.82(-0.86%)
U.S. Market opens in 49h 27m

Incyte Corporation (INCY) Stock Overview

Explore Incyte Corporation’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

Z

Key Financials

Market Cap18.8B
P/E Ratio14.59
EPS (TTM)$6.41
ROE0.29%
Fundamental Analysis

AI Price Forecasts

1 Month$86.04
3 Months$102.87
1 Year Target$118.06

INCY Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Incyte Corporation (INCY) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 47.36, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $118.06.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 14.59 and a market capitalization of 18.8B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

1-Day Change
-0.86%
5-Day Change
-2.02%
1-Month Change
4.45%
3-Month Change
-7.20%
6-Month Change
3.69%
Year-to-Date (YTD) Change
-4.17%
1-Year Change
60.51%
3-Year Change
25.78%
5-Year Change
10.56%
All-Time (Max) Change
4948.00%

Contact Information

https://www.incyte.com
302 498 6700
1801 Augustine Cut-Off, Wilmington, DE, 19803

Company Facts

2,617 Employees
IPO DateNov 4, 1993
CountryUS
Actively Trading

Frequently Asked Questions